{"id":"W4392157493","doi":"10.1177/17562864231221331","title":"Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"National Health and Medical Research Council; Sanofi Genzyme; Grifols; Všeobecná Fakultní Nemocnice v Praze; Sanofi; European Commission; Canadian Institutes of Health Research; Multiple Sclerosis Australia; Teva Pharmaceutical Industries; Univerzita Karlova v Praze; Medical Research Council; Biogen; Celgene","keywords":"Natalizumab; Medicine; Multiple sclerosis; Disease; Fingolimod; First line therapy; Glatiramer acetate; Clinical significance; Teriflunomide; Intensive care medicine; Oncology; Internal medicine; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003156686,0.0006220154,0.001182898,0.0002853972,0.0002117605,0.00009981995,0.0003429765,0.0001228429,0.00004776517],"category_scores_gemma":[0.0002640965,0.0003361497,0.0001531817,0.0008085016,0.001044911,0.0005138965,0.0001240177,0.001023527,0.000005413759],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006180254,"about_ca_system_score_gemma":0.00007387856,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002468594,"about_ca_topic_score_gemma":0.001711068,"domain_scores_codex":[0.9959839,0.0003913784,0.0007146555,0.001122473,0.0009324685,0.0008551087],"domain_scores_gemma":[0.9967231,0.002202411,0.0001953369,0.00053191,0.0001195397,0.000227677],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01528655,0.001709092,0.8962026,0.000234288,0.0002793455,0.00008799367,0.000408957,0.001616752,0.000001784156,0.00001418101,0.000001823984,0.08415661],"study_design_scores_gemma":[0.01598152,0.003882892,0.9747562,0.001271071,0.00005307433,0.000001710651,0.0001669589,0.003101618,0.000001851189,0.0001095452,0.0002364773,0.0004370667],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9831077,0.01155164,0.0006260621,0.002087466,0.0000833927,0.002183543,0.00004538833,0.0002374296,0.00007736928],"genre_scores_gemma":[0.977885,0.0198983,0.0002950717,0.001320504,0.00004207019,0.0004062331,0.0000455382,0.00009608681,0.00001115745],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08371954,"threshold_uncertainty_score":0.999909,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09250910395706537,"score_gpt":0.3612026078689723,"score_spread":0.268693503911907,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}